Monday, July 7, 2014

International Stem Cell Corp. (ISCO) Firmly Rooted in Biotech Space with Innovative Technology, Unique Business Model

International Stem Cell Corp., the developer of a new stem cell technology called parthenogenesis, is focused on the application of its research and development to the treatment of human degenerative diseases.

The company’s human parthenogenetic stem cells (hpSCs), derived from unfertilized human eggs, have the best characteristics of each of the most commonly used and described classes of stem cells – induced pluripotent stem cells, embryonic stem cells, and adult stem cells – thereby creating a class of cells that meet all important criteria when it comes to therapeutic application.

hsPCs’ are immune matching, which means that millions of patients could receive tissue and cell transplants without tissue rejection problems or the need to take immune-suppressing drugs; pluripotent, meaning they can change or “differentiate” into more specialized cells such as skin, liver or blood cells; demonstrate strong proliferation in culture, which refers to the growth of the cell populations in the research and/or application environment; and are considered superior in their use in genetic disease.

Leveraging these capabilities and characteristics, International Stem Cell aims to use its hsPCs to treat diseases of the brain (Parkinson’s diseases), liver (treatment of liver damage) and eye (cornea tissue implants). In support of these goals, the company is also building its stem cell bank (UniStemCell) of parthenogenetic stem cell lines for research and commercial use.

International Stem Cell’s subsidiary business units, Lifeline Cell Technology (LCT) and Lifeline Skin Care (LSC), further support the company and create a business model unique to the biotechnology industry, creating revenue flow from the sale of products develop from scientific discoveries made by International Stem Cell. This self-sustaining model not only allows for the allocation of revenues to further support scientific research and development, but also provides practical, short-term applications of the company’s core technologies.

For more information visit www.internationalstemcell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: